VEGFA and meningioma: The current study results suggest that BEV, a humanized VEGF ligand binding monoclonal antibody, improves PFS-6 in patients with refractory meningiomas as reflected by a 90% rate in Grade I and 66% rate in Grade II/III meningiomas.